NEW YORK (GenomeWeb News) – Lab services provider Genoptix said today that it has signed a license and collaboration agreement with HistoRx covering cancer biomarker analysis technologies in the US.
The license gives Carlsbad, Calif.-based Genoptix the exclusive commercial laboratory rights to develop and perform in the US three solid tumor assays using HistoRx's Aqua technology. In addition, it has gained non-exclusive rights to use Aqua to measure two other biomarkers that have been associated with many cancers.
The Aqua technology is used in fluorescent immunohistochemstry analysis, and enables users to assess specific biomarkers for patients with solid tumors by measuring the protein in a cell's cytoplasm or nucleus.
Under the agreement, Genoptix and HistoRx may collaborate to develop additional assays that Genoptix would then have the rights to commercialize. Financial terms of the agreement were not released.